X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
Duaklir (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) are inhaled respiratory medicines used for the maintenance treatment of COPD. Eklira is a LAMA and Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2-agonist (LABA).
Lead Product(s): Aclidinium Bromide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Duaklir
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Under the terms of the Acquisition agreement, Covis Pharma has completed the acquisition of Eklira® (aclidinium bromide), known as Tudorza® in US and marketed as Bretaris® in some countries, and Duaklir® (aclidinium bromide/formoterol), marketed as Brimica®, from AstraZeneca.
Lead Product(s): Aclidinium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Eklira
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Covis Pharma
Deal Size: $270.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 05, 2022
Details:
Covis Pharma acquired the rights of Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol), inhaled respiratory medicines used for the maintenance treatment of COPD from AstraZeneca.
Lead Product(s): Aclidinium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Eklira
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Covis Pharma
Deal Size: $270.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 01, 2021
Details:
On completion of the Transaction, AstraZeneca will acquire the U.S. commercial rights to Tudorza® and Duaklir® together with certain ancillary rights and assets, from Circassia.
Lead Product(s): Aclidinium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Circassia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination April 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
